Table 1.
Patient characteristics
| Characteristic | PD-L1 (−/−) (n = 52) | PD-L1 (−/+) (n = 19) | PD-L1 (+/−) (n = 12) | PD-L1 (+/+) (n = 26) | Total (n = 109) | p value |
|---|---|---|---|---|---|---|
| Age, yr | 65.5 (29–88) | 69 (53–80) | 73 (44–88) | 64 (49–81) | 67 (29–88) | 0.271 |
| Male sex | 33 (63.5) | 14 (73.7) | 10 (83.3) | 20 (76.9) | 77 (70.6) | 0.477 |
| Smoking status | 0.727 | |||||
| Current/former smokers | 32 (61.5) | 13 (68.4) | 9 (75.0) | 19 (73.1) | 73 (67.0) | |
| Never smokers | 20 (38.5) | 6 (31.6) | 3 (25.0) | 7 (26.9) | 36 (33.0) | |
| ECOG at diagnosis | 0.412 | |||||
| 0 | 17 (32.7) | 9 (47.4) | 1 (8.3) | 10 (38.5) | 37 (34.0) | |
| 1 | 31 (59.6) | 9 (47.4) | 10 (83.3) | 14 (53.8) | 64 (58.7) | |
| 2 | 4 (7.7) | 1 (5.3) | 1 (8.3) | 2 (7.7) | 8 (7.3) | |
| Histology | 0.085 | |||||
| Adenocarcinoma | 34 (65.4) | 12 (63.2) | 4 (33.3) | 20 (76.9) | 70 (64.2) | |
| Others | 18 (34.6) | 7 (36.8) | 8 (66.7) | 6 (23.1) | 39 (35.8) | |
| Disease stage at diagnosis | 0.237 | |||||
| I | 5 (9.6) | 3 (15.8) | 2 (16.7) | 2 (7.7) | 12 (11.0) | |
| II | 4 (7.7) | 1 (5.3) | 3 (25.0) | 0 | 8 (7.3) | |
| III | 9 (17.3) | 6 (31.6) | 1 (8.3) | 5 (19.2) | 21 (19.3) | |
| IV | 34 (65.4) | 9 (47.4) | 6 (50.0) | 19 (73.1) | 68 (62.4) | |
| Status of oncogenic alteration | ||||||
| EGFR mutation | 17 (32.7) | 7 (36.8) | 2 (16.7) | 5 (19.2) | 31 (28.4) | 0.432 |
| Others | 4 (7.7) | 1 (5.3) | 1 (8.3) | 6 (23.1) | 12 (11.0) | 0.183 |
| Follow-up duration, mo | 25.53 (2.3–111.2) | 43.0 (9.3–162.2) | 38.1 (19.2–86.2) | 23.8 (8.5–49.1) | 32.1 (2.3–162.2) | 0.140 |
Values are presented as median (range) or number (%).
PD-L1, programmed death-ligand 1; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.